According to Advances in Biopharmaceutical Technology in China, 2nd Ed, a report from BioPlan Associates, China is making strides in raising its Good Manufacturing Process (GMP) standards as it works to improve its global profile. GMP biopharmaceutical manufacturing has a short history in China, with the first version of guidance issued in 1998. In 2010, China's Ministry of Health released its fourth version of China GMP, with this iteration significantly raising the standards to be met by domestic biopharmaceutical developers.

Many have questioned whether China can move from "the world's factory” for consumer goods, electronics, and commodities, into technologically complex biologics.

It shouldn’t come as a surprise that biopharma in China is growing faster than many in the West have projected. A number of economic and development factors are contributing to this growth. But these have all been evolving for decades. 

So if there is a gap in Western (and in some cases China’s own internal) knowledge about this evolution, it should be put down to simply not paying enough attention.  

The next generation sequencing (NGS) market has captured the interest of many companies and investors across a variety of applications including clinical diagnostics, drug discovery and development, forensics, and consumer genomics, to name a few.

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a variety of important cellular functions. One of their important functions is to transfer DNA, RNA, and proteins to other cells.

For years, exosomes were considered to be transporters of cellular waste, but now they are becoming recognized for their critical role in cell-to-cell communication and transportation.

According to a new market research report by BIS Research titled Global Precision Medicine Market – Analysis and Forecast (2017-2026), the global precision medicine market is expected to reach a value of $141.7 billion by the year 2026, wherein the oncology market segment is expected to grow at a compound annual growth rate (CAGR) of 10.4% from 2017 to 2026.

3D bioprinting artificially constructs living tissue by applying layer-upon-layer of living cells. The deposition of live cells in combination with biological substances such as collagen, fibrin, and gelatin supports the growth of complete tissues and organs.

MarketResearch.com has five in-house publishing divisions that produce quality market intelligence for top industry decision makers. 

These publishers not only provide market research reports, they have also released a number of free white papers, presentations, and e-books on a variety of dynamic markets. These resources are designed to give you a quick view of an industry, leading companies, or trends. 

Kalorama Information, a leading healthcare market research firm, just released a new e-book titled 15 Biotech Companies to Watch. This free resource covers a variety of innovative biotechnology companies and provides detailed information on novel products, emerging technologies, and M&A activity.

I caught up with Bruce Carlson, the Publisher of Kalorama Information, to hear more about the e-book and the biotechnology industry as a whole. Read the Q&A below for his unique insights into this rapidly evolving sector.

The field of gene editing is expanding rapidly. A team of scientists in China recently injected CRISPR-edited cells into a human patient for the first time — potentially setting off a biomedical race between China and the United States, as reported in the international scientific journal Nature.

More significant developments are expected in the years to come. The global CRISPR market is forecast to grow at an astonishing compound annual growth rate (CAGR) of 35% from 2016 to 2022, according to Inkwood Research, a market intelligence firm. The number of scientific papers published on CRISPR continues to soar, from below 200 papers in 2012 to more than 1,200 papers in 2015.